Post Approval Study of the CyPass System

NCT ID: NCT03273907

Last Updated: 2024-02-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

79 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-10-12

Study Completion Date

2021-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate that the rate of clinically relevant complications associated with CyPass Micro-Stent placement and stability using the CyPass 241-S applier, as determined at 36 months in the postmarket setting, is less than the pre-specified performance target, which is based on experience with the CyPass Model E applier in COMPASS trial TMI-09-01 (NCT01085357).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Each subject's expected participation in the study is up to 37.5 months which includes up to 42 days between the screening and surgery visits, and 36 months of post-surgery follow-up. Only one eye per subject will be implanted.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Open-angle Glaucoma Cataract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CyPass System

CyPass Micro-Stent implanted with CyPass 241-S applier in the angle of the eye during cataract surgery

Group Type EXPERIMENTAL

CyPass Micro-Stent implanted with CyPass 241-S applier

Intervention Type DEVICE

CyPass System (Model 241-S) consists of the CyPass Micro-Stent contained in a loading device (loader) and the CyPass applier.The CyPass Micro-Stent is an implantable medical device intended for long term use.

Cataract surgery

Intervention Type PROCEDURE

Cataract surgery, followed by implantation of the CyPass Micro-Stent in one eye (the study eye) at the surgery visit

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CyPass Micro-Stent implanted with CyPass 241-S applier

CyPass System (Model 241-S) consists of the CyPass Micro-Stent contained in a loading device (loader) and the CyPass applier.The CyPass Micro-Stent is an implantable medical device intended for long term use.

Intervention Type DEVICE

Cataract surgery

Cataract surgery, followed by implantation of the CyPass Micro-Stent in one eye (the study eye) at the surgery visit

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to understand the requirements of the study and willing to follow study instructions, provide written informed consent, and agree to comply with all study requirements, including the required study follow-up visits
* Diagnosis of primary open angle glaucoma (POAG)
* Medicated intraocular pressure (IOP) of ≥10 millimeters mercury (mmHg) and ≤25 mmHg, or an unmedicated IOP of ≥21 mmHg and ≤33 mmHg
* An operable age-related cataract eligible for phacoemulsification
* Visual acuity as specified in the protocol

Exclusion Criteria

* Inability to complete a visual field test prior to surgery
* Use of ocular hypotensive medication/s, as specified in the protocol
* Diagnosis of glaucoma other than POAG, as specified in the protocol
* Other medical conditions, as specified in the protocol
* Proliferative diabetic retinopathy
* Previous surgery for retinal detachment
* Previous corneal surgery
* Wet age-related macular degeneration
* Poor vision in the non-study eye not due to cataract
* Significant ocular inflammation or infection within 30 days of screening visit
* Uncontrolled systemic diseases that may put the subject's health at risk and/or prevent the subject from completing all study visits
* Women who are pregnant or nursing
Minimum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Alcon Research

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sr. Clinical Trial Lead, Surgical

Role: STUDY_DIRECTOR

Alcon Research, LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Alcon Investigative Site

Phoenix, Arizona, United States

Site Status

Alcon Investigative Site

Orange, California, United States

Site Status

Alcon Investigative Site

Fort Collins, Colorado, United States

Site Status

Alcon Investigative Site

Jacksonville, Florida, United States

Site Status

Alcon Investigative Site

Panama City, Florida, United States

Site Status

Alcon Investigative Site

Gainesville, Georgia, United States

Site Status

Alcon Investigative Site

Marietta, Georgia, United States

Site Status

Alcon Investigative Site

Garden City, Kansas, United States

Site Status

Alcon Investigative Site

Fraser, Michigan, United States

Site Status

Alcon Investigative Site

St Louis, Missouri, United States

Site Status

Alcon Investivative Site

St Louis, Missouri, United States

Site Status

Alcon Investigative Site

Vineland, New Jersey, United States

Site Status

Alcon Investigative Site

Bala-Cynwyd, Pennsylvania, United States

Site Status

Alcon Investigative Site

Chambersburg, Pennsylvania, United States

Site Status

Alcon Investigative Site

Austin, Texas, United States

Site Status

Alcon Investigative Site

El Paso, Texas, United States

Site Status

Alcon Investigative Site

Houston, Texas, United States

Site Status

Alcon Investigative Site

Bellevue, Washington, United States

Site Status

Alcon Investigative Site

Kenosha, Wisconsin, United States

Site Status

Alcon Investigative Site

Racine, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GLD122c-C001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.